Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations

Nathalie Van den Berghe(KU Leuven), Debby Thomas(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Séverine Vermeire(KU Leuven), Paul Declerck(KU Leuven), João Sabino(KU Leuven), Ann Gils(KU Leuven)
Journal of Crohn s and Colitis
November 18, 2020
10.1093/ecco-jcc/jjaa239
Cited by 15

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k